PhD Jadwiga Wardas



Education, scientific degrees I graduated from the Jagiellonian University in Krakow, Department of Biology and Earth Sciences, Poland with an MSc in biology. In 1988 I was granted a fellowship from the National Academy of Sciences, USA and I stayed at the Department of Neurology, Jefferson Medical College in Philadelphia (1988, 2.5 month) and at the Department of Pharmacology, Georgetown University Medical Center in Washington, DC, USA – 1988-1989 (1 year); 

I hold a Ph.D. (1991) in Life Sciences from the Institute of Pharmacology, Polish Academy of Sciences, Krakow. I was qualified as Associate Professor at the Department of Neuropsychopharmacolgy, Institute of Pharmacology, Polish Academy of Sciences, Krakow (2004, Habilitation).

Cooperation: I have collaborated in research for more than 20 years with Prof. M. Morelli (University of Cagliari, Italy). Department of Toxicology, Centre of Excellence for Neurobiology of Dependence, University of Cagliari, Cagliari (Italy): 1993 (3 month); 1995 (2 month); 1997 (2 month), 1998 (1.5 month) and since 1999 up till 2007 – several short term research stays (up to 10 days), in the frame of the Polish-Italian Government Cooperation;

Moreover, we cooperated with the Department of Neuro-Psychopharmacology, Free University of Berlin, (Germany) for many years (1994 - 2000 - several short stays).

I have been awarded numerous competitive research grants (including Polish-Italian grants) by the State Committee for Scientific Research and National Science Centre.

My scientific interests focus on the pathophysiology and therapy of Parkinson’s disease and development of animal models of both presymptomatic and symptomatic phase of this disease. Since many years I was studied the involvement of adenosine and dopamine receptors in antiparkinsonian and neuroprotective effects.

Current  membership in scientific societies - Polish Neuroscience Society, FENS

I am the author (co-author) of 70 original publications and 115 conference abstracts; Total 1583 citations; without self-citation = 1488, as for 13.05.2016, according to ISI Web of SCIENCE. Index H = 24

more_publications
  • “Control of Motor Function by Adenosine A2A Receptors in Parkinson’s and Huntington’s Disease”

    chapter in the book:

    Pinna A., Wardas J., Domenici M. R., Popoli P., Cossu G. and Morelli M. “Control of Motor Function by Adenosine A2A Receptors in Parkinson’s and Huntington’s Disease” In: Blum D, Lopes LV, eds., "Adenosine Receptors in Neurodegenerative Diseases", San Diego: Academic Press, 2017: 188-214. 

  • Adenosine A2A receptors: Localization and Function.

    Simola N. and WARDAS J.: Adenosine A2A receptors: Localization and Function. (chapter 1)

    In: “The Adenosinergic System. A non-dopaminergic target in Parkinson’s disease” Eds. Morelli M, Simola N., Wardas J. Springer International Publishing Switzerland, 2015, pp. 1-25; Current Topics in Neurotoxicity, vol. 10 (Series Eds. Kostrzewa R., Archer T.).

  • Motor thalamic nuclei as a potential therapeutic target for adenosine in parkinsonian and essential tremor; behavioural, neurochemical and molecular studies in rats - 2014-08-21 - 2018-08-20
    1.    Research project objectives/Research hypothesis Essential (ET) and parkinsonian (PD) tremors are relatively frequent neurological disorders in humans. Since mechanisms underlying  these tremors are only poorly understood, current pharmacological therapies of these disturbances are highly insufficient. Therefore, there is an urgent need to search for these mechanisms and find out drugs which would be effective at the clinic.The ventral motor thalamus seems to be a brain structure crucial to relay and integrate impulses related to both PD tremor and ET. This region receives glutamatergic inputs from the cerebellum and GABAergic projections from the basal ganglia and therefore seems to be important for convergence of the cerebellar and basal ganglia informations.  The present project is devoted to examine whether adenosine and its receptors may be a target for future pharmacotherapy of ET and/or PD tremor. Since adenosine receptors (A1 and A2A) are present in neuronal networks of the ventral thalamic nuclei, the project is focused at examination of a modulatory role of adenosine receptor ligands on ET and PD tremor in animal models and a contribution of the cerebello-thalamic vs basal ganglia-thalamic circuits in these phenomena.  

national

international

  • Dept. of Biomedical Sciences Section of Neuropsychopharmacology, University of Cagliari, Italy
Copyright © 2017